about
Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular TherapiesMono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.Targeting non-Hodgkin lymphoma with blinatumomab.The making of bispecific antibodiesTherapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.Progress in biopharmaceutical development.Bispecific antibodies in cancer immunotherapy.Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapyBi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
P2860
Q38651290-EB5AA97C-17C7-4EC1-9CDF-383D3ED455A2Q38739764-65D6EAEE-F064-4DA8-9C2E-887182074093Q38770594-7C23D4D5-E65A-4558-8599-D561F5C60903Q42323236-9220BCCF-3C41-4641-AE20-A201991AF8B9Q43525091-2B6C6FD0-39AB-4D42-8A36-3C7FFF59F780Q48253463-BA567E0A-0654-47D6-98F7-84422C12DD6AQ51309023-7B1780B6-8C55-433D-BE24-7FD9623B0736Q56890857-EE4BD1AB-DBD6-4E24-AC18-795BC5C20E74Q57151874-FA808F8E-1037-4782-B4F9-4ECDEF479373
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A review of blinatumomab, a novel immunotherapy.
@en
type
label
A review of blinatumomab, a novel immunotherapy.
@en
prefLabel
A review of blinatumomab, a novel immunotherapy.
@en
P2860
P356
P1476
A review of blinatumomab, a novel immunotherapy
@en
P2093
Dina J Benani
P2860
P304
P356
10.1177/1078155215618770
P577
2015-11-24T00:00:00Z